STAT November 20, 2023
Richard Burr

Cell and gene therapies are the next frontier in medicine and promise long-sought hope for people living with incurable and fatal conditions. As their promise increasingly becomes reality, the FDA’s gatekeeping role is important.

To truly serve the people who need these medications, the FDA must be a good-faith partner and deploy the tools my fellow congressional lawmakers and I helped secure.

We are finally beginning to realize the results of decades of cell and gene therapy investments, fostered by repeated bipartisan legislation to help advance the scientific technology capable of addressing diseases at the DNA level. Despite signs of progress and a strong commitment from FDA leadership to improve its readiness for these cutting-edge therapies, the agency remains far...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
The telehealth background of Trump's FDA pick: 6 notes
President-elect Trump's picks for CDC, FDA, surgeon general: 31 notes
Opinion: RFK Jr. and MAHA should champion a Marshall Plan for obesity
Trump picks Johns Hopkins surgeon to head FDA: 10 things to know
Regulatory Hurdles and Ethical Concerns Beset FDA Oversight of AI/ML Devices

Share This Article